Business
Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration
NEW BRUNSWICK, N.J., January 07, 2026--Johnson & Johnson today announced that the company has submitted the OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification. Leveraging data from the Investigational Device Exemption (IDE) study, the company has applied for marketing authorization in multiple procedures in general surgery within the upper abdomen.
About this update from Johnson & Johnson
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2404,"height":224,"url":"https://media.zenfs.com/en/business-wire.com/a7e7ac6afc410f8bc852ca7060716773"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C66P86Ex3ZVHLlwMcgY5oQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTg5O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/a7e7ac6afc410f8bc852ca7060716773","width":960,"height":89},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/McVbpZbIu42r2JfPyWGnCQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0yMjQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/a7e7ac6afc410f8bc852ca7060716773","width":1200,"height":112}},"lazy":false},{"type":"text","content":"Data from Investigational Device Exemption (IDE) study in Roux-en-Y gastric bypass procedures used to support application for De Novo classification","length":148,"tagName":"p","attribs":{}},{"type":"text","content":"Second IDE approved for U.S. clinical trial for OTTAVA in inguinal hernia procedures","length":84,"tagName":"p","attribs":{}},{"type":"text","content":"NEW BRUNSWICK, N.J., January 07, 2026--(BUSINESS WIRE)--Johnson & Johnson today announced that the company has submitted the OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification. Leveraging data from the Investigational Device Exemption (IDE) study, the company has applied for marketing authorization in multiple procedures in general surgery within the upper abdomen.","length":444,"tagName":"p"},{"type":"text","content":""We have taken learnings from Johnson & Johnson’s 140 years in surgery, our decades of leadership in minimally invasive surgery, and the experiences robotic surgeons and hospitals have had over the past 20 years to design a soft tissue robotic system built for the future of surgery," said Hani Abouhalka, Company Group Chair, Surgery, MedTech, Johnson & Johnson. "I am proud of the design decisions and major scientific efforts that have gone into the system to support surgeons and successfully complete our first clinical trial, and I look forward to reaching the next milestone on our path to commercialization."","length":644,"tagName":"p"},{"type":"text","content":"Data from first clinical trial supporting submissionFirst ...